Hyunseok Kang, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #L5172
San Francisco CA 94158
ORCID ORCID Icon0000-0001-5758-8202 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yonsei University, Seoul, KoreaM.D.02/2002Medicine
    Yonsei University, Seoul, KoreaM.P.H.08/2007Epidemiology & Statistics
    St.Luke's-Roosevelt Hospital/Columbia University, New York, NYResidency06/2010Internal Medicine
    Emory University, Atlanta, GAFellowship06/2013Hematology&Oncology
    University of California, San Francisco, CA06/2021Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    Ministry of Health and Welfare of Korea2005  - 2005Excellence in Service Award
    AACR/ASCO2012  - 2012Travel Award for Methods in Clinical Research Workshop
    American College of Physicians2015Elected to a fellow (FACP)

    Collapse Overview 
    Collapse Overview
    Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck. Dr.Kang joined UCSF from the Johns Hopkins University School of Medicine in Baltimore, MD where he was an Assistant Professor of Oncology, Otolaryngology - Head and Neck Surgery.

    Dr.Kang completed his medical degree and public health degree at Yonsei University in Seoul, South Korea, then came to the US and had residency training at St.Luke's Roosevelt Hospital Center/Columbia University in New York City. He completed hematology and medical oncology fellowship at Emory University in Atlanta, GA.

    Dr.Kang's research focus is development of clinical trials with novel therapeutic agents for patients with head and neck cancers. He has conducted/participated a number of clinical trials with immune checkpoint inhibitors and targeted therapy agents.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. ESMO Open. 2024 May; 9(5):103444. Raez LE, Kang H, Ohe Y, Khanal M, Han Y, Szymczak S, Barker SS, Gilligan AM. PMID: 38749381; PMCID: PMC11108846.
      View in: PubMed   Mentions: Translation:HumansCTClinical Trials
    2. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. Oral Oncol. 2024 Feb; 149:106634. Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. PMID: 38118249.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Carboplatin and paclitaxel after anti-PD-1 or anti-PD-L1 antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck. Head Neck. 2024 Feb; 46(2):321-327. Humphries A, Zhou CJ, Welsh M, Lem M, Kang H, Algazi AP. PMID: 37997549.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2023 11 14; 29(22):4555-4563. Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. PMID: 37643133; PMCID: PMC10643996.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    5. The neutrophil-to-lymphocyte ratio in salivary gland cancers treated with pembrolizumab. Head Neck. 2024 Jan; 46(1):129-137. Lee RH, Truong A, Wu X, Kang H, Algazi AP, El-Sayed IH, George JR, Heaton CM, Ryan WR, Ha PK, Wai KC. PMID: 37897202.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma. Laryngoscope. 2024 Apr; 134(4):1687-1695. Plonowska-Hirschfeld KA, Gulati A, Stephens EM, Ochoa E, Xu MJ, Ha PK, Heaton CM, Yom SS, Chan JW, Algazi A, Kang H, Ryan WR. PMID: 37767815.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. A prospective evaluation of neck and shoulder function following treatments of early-stage human papillomavirus-associated oropharynx cancer. Clin Otolaryngol. 2023 Sep; 48(5):756-765. Gulati A, Plonowska-Hirschfeld K, Stephens EM, Kansara S, Zebolsky AL, Ochoa E, Xu MJ, Ha PK, Heaton CM, Yom SS, Chan JW, Algazi AP, Kang H, Ryan WR. PMID: 37212448.
      View in: PubMed   Mentions:    Fields:    
    8. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 12 08; 114(12):1619-1627. Rodriguez CP, Kang H, Geiger JL, Burtness B, Chung CH, Pickering CR, Fakhry C, Le QT, Yom SS, Galloway TJ, Golemis E, Li A, Shoop J, Wong S, Mehra R, Skinner H, Saba NF, Flores ER, Myers JN, Ford JM, Karchin R, Ferris RL, Kunos C, Lynn JM, Malik S. PMID: 36053203; PMCID: PMC9745425.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Med. 2023 03; 12(6):6603-6614. Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM. PMID: 36479637; PMCID: PMC10067081.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    10. Approaches to the Management of Metastatic Adenoid Cystic Carcinoma. Cancers (Basel). 2022 Nov 20; 14(22). Lee RH, Wai KC, Chan JW, Ha PK, Kang H. PMID: 36428790.
      View in: PubMed   Mentions: 8  
    11. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 10; 23(10):1261-1273. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. PMID: 36108661.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    12. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). J Clin Oncol. 2022 12 20; 40(36):4240-4249. Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. PMID: 35867947; PMCID: PMC9916043.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    13. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology. J Clin Endocrinol Metab. 2022 07 14; 107(8):e3206-e3216. Soe MH, Chiang JM, Flavell RR, Khanafshar E, Mendoza L, Kang H, Liu C. PMID: 35556126; PMCID: PMC9282362.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    14. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022 02; 10(2). Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. PMID: 35217573; PMCID: PMC8883256.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    15. Real-World Experience of NTRK Fusion-Positive Thyroid Cancer. JCO Precis Oncol. 2022 02; 6:e2100442. Park JC, Ashok A, Liu C, Kang H. PMID: 35171659; PMCID: PMC8865519.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    16. What’s New in Molecular Targeted Therapies for Thyroid Cancer? Korean J Head Neck Oncol. 2021; 2(37):1-9. Min S, Kang H. View Publication.
    17. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. J Clin Invest. 2021 11 15; 131(22). Jin N, Keam B, Cho J, Lee MJ, Kim HR, Torosyan H, Jura N, Ng PK, Mills GB, Li H, Zeng Y, Barbash Z, Tarcic G, Kang H, Bauman JE, Kim MO, VanLandingham NK, Swaney DL, Krogan NJ, Johnson DE, Grandis JR. PMID: 34779417; PMCID: PMC8592538.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    18. Effect of chemotherapy and radiotherapy on cognitive impairment in colorectal cancer: evidence from Korean National Health Insurance Database Cohort. Epidemiol Health. 2021; 43:e2021093. Kim K, Kim CW, Shin A, Kang H, Jung SJ. PMID: 34735757; PMCID: PMC8920736.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes. Clin Cancer Res. 2021 10 01; 27(19):5168-5187. Lee RH, Kang H, Yom SS, Smogorzewska A, Johnson DE, Grandis JR. PMID: 34045293; PMCID: PMC8626541.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    20. Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by FANCM Mutations. JCO Precis Oncol. 2021; 5. Vellanki PJ, DeBoy EA, Bawadkji MM, Schuchter L, Rooper L, Mehra R, Kang H, Armanios M. PMID: 34568721; PMCID: PMC8457871.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Molecular Markers that Matter in Salivary Malignancy. Otolaryngol Clin North Am. 2021 Jun; 54(3):613-627. Wai KC, Kang H, Ha PK. PMID: 34024488.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Res. 2021 02 15; 81(4):1001-1013. Humtsoe JO, Kim HS, Leonard B, Ling S, Keam B, Marchionni L, Afsari B, Considine M, Favorov AV, Fertig EJ, Kang H, Ha PK. PMID: 33408119.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    23. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. Mol Cancer Res. 2021 01; 19(1):14-24. Cui Z, Kang H, Grandis JR, Johnson DE. PMID: 32883697; PMCID: PMC7840145.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    24. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. PMID: 32846061; PMCID: PMC10777663.
      View in: PubMed   Mentions: 235     Fields:    Translation:HumansCTClinical Trials
    25. The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma. Oral Oncol. 2020 09; 108:104935. Park JC, Durbeck J, Boudadi K, Ho WJ, Kang H. PMID: 32792211.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Squamous cell carcinoma of head and neck: what internists should know. Korean J Intern Med. 2020 09; 35(5):1031-1044. Jung K, Narwal M, Min SY, Keam B, Kang H. PMID: 32663913; PMCID: PMC7487309.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    27. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421. Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. PMID: 32067683.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    28. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head Neck. 2018 12; 40(12):E100-E106. Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H. PMID: 30478962.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    29. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head Neck. 2018 12; 40(12):2612-2620. Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. PMID: 30421818.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Oncologist. 2019 06; 24(6):791-797. Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM. PMID: 30373905; PMCID: PMC6656481.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    31. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. N Engl J Med. 2018 Oct 18; 379(16):1578-1579. Kwatra SG, Ständer S, Kang H. PMID: 30332571.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. Oncologist. 2019 02; 24(2):146-150. Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. PMID: 30297384; PMCID: PMC6369939.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. J Immunother Cancer. 2018 08 31; 6(1):84. Ho WJ, Yarchoan M, Hopkins A, Mehra R, Grossman S, Kang H. PMID: 30170629; PMCID: PMC6117944.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    34. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiol Health. 2018; 40:e2018040. Jung K, Park JC, Kang H, Brandes JC. PMID: 30121970; PMCID: PMC6232654.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion: Expanding the Molecular Spectrum of a Recently Described Entity. Am J Surg Pathol. 2018 08; 42(8):1121-1126. Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. PMID: 29683815.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    36. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 07; 119(2):153-159. Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R. PMID: 29955135; PMCID: PMC6048158.
      View in: PubMed   Mentions: 187     Fields:    Translation:HumansCTClinical Trials
    37. Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncol. 2018 09; 84:134-136. Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL. PMID: 30122219.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. J Immunother Cancer. 2018 05 09; 6(1):33. Ho WJ, Rooper L, Sagorsky S, Kang H. PMID: 29743117; PMCID: PMC5943998.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    39. Short- and long-term outcomes of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 09; 128(9):2084-2093. Motz K, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Eisele DW, Koch WM, Frick KD, Gourin CG. PMID: 29573418.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. Quality indicators of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 10; 128(10):2312-2319. Gourin CG, Herbert RJ, Fakhry C, Quon H, Kang H, Kiess AP, Koch WM, Eisele DW, Frick KD. PMID: 29243261.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Treatment, survival, and costs of oropharyngeal cancer care in the elderly. Laryngoscope. 2018 05; 128(5):1103-1112. Gourin CG, Fakhry C, Quon H, Kang H, Kiess AP, Herbert RJ, Eisele DW, Frick KD. PMID: 28988469.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol. 2017 11; 74:40-48. Schmitt NC, Kang H, Sharma A. PMID: 29103750; PMCID: PMC5685667.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    43. High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget. 2017 Dec 19; 8(67):110931-110948. Guerrero-Preston R, White JR, Godoy-Vitorino F, Rodríguez-Hilario A, Navarro K, González H, Michailidi C, Jedlicka A, Canapp S, Bondy J, Dziedzic A, Mora-Lagos B, Rivera-Alvarez G, Ili-Gangas C, Brebi-Mieville P, Westra W, Koch W, Kang H, Marchionni L, Kim Y, Sidransky D. PMID: 29340028; PMCID: PMC5762296.
      View in: PubMed   Mentions: 41     Fields:    
    44. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. Cancer Metastasis Rev. 2017 09; 36(3):449-461. Fung N, Faraji F, Kang H, Fakhry C. PMID: 28812214.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    45. Quality indicators of laryngeal cancer care in commercially insured patients. Laryngoscope. 2017 12; 127(12):2805-2812. Britt CJ, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. PMID: 28688188.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    46. Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. Laryngoscope. 2018 01; 128(1):91-101. Day AT, Chang HY, Quon H, Kang H, Kiess AP, Eisele DW, Frick KD, Gourin CG. PMID: 28685830.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. JCO Precis Oncol. 2017; 2017. Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J. PMID: 30003184; PMCID: PMC6039131.
      View in: PubMed   Mentions: 42     Fields:    
    48. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clin Cancer Res. 2017 Sep 01; 23(17):5162-5175. Ozawa H, Ranaweera RS, Izumchenko E, Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A, Ravi R, Perez J, Le QT, Kong CS, Jordan RC, Wang H, Kang H, Quon H, Sidransky D, Chung CH. PMID: 28522603; PMCID: PMC6078415.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    49. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. PMID: 28328302; PMCID: PMC5946724.
      View in: PubMed   Mentions: 283     Fields:    Translation:HumansCTClinical Trials
    50. Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. JAMA Oncol. 2017 Feb 01; 3(2):169-177. D'Souza G, Westra WH, Wang SJ, van Zante A, Wentz A, Kluz N, Rettig E, Ryan WR, Ha PK, Kang H, Bishop J, Quon H, Kiess AP, Richmon JD, Eisele DW, Fakhry C. PMID: 27930766; PMCID: PMC7286346.
      View in: PubMed   Mentions: 66     Fields:    
    51. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. Cancer. 2017 05 15; 123(10):1768-1777. Malm IJ, Fan CJ, Yin LX, Li DX, Koch WM, Gourin CG, Pitman KT, Richmon JD, Westra WH, Kang H, Quon H, Eisele DW, Fakhry C. PMID: 28055120.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    52. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2017 03; 7(3):264-276. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. PMID: 28031159; PMCID: PMC5733805.
      View in: PubMed   Mentions: 447     Fields:    Translation:Humans
    53. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 11 10; 34(32):3838-3845. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. PMID: 27646946; PMCID: PMC6804896.
      View in: PubMed   Mentions: 404     Fields:    Translation:Humans
    54. Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res. 2017 Jan 01; 23(1):283-288. Kang H, Tan M, Bishop JA, Jones S, Sausen M, Ha PK, Agrawal N. PMID: 27340278; PMCID: PMC5182193.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    55. FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. AJR Am J Roentgenol. 2016 May; 206(5):1093-100. Taghipour M, Sheikhbahaei S, Wray R, Agrawal N, Richmon J, Kang H, Subramaniam RM. PMID: 26999264.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    56. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb; 53:54-9. Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. PMID: 26705063; PMCID: PMC4707116.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    57. Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. AJR Am J Roentgenol. 2015 Nov; 205(5):1102-13. Sheikhbahaei S, Ahn SJ, Moriarty E, Kang H, Fakhry C, Subramaniam RM. PMID: 26496559.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    58. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun 24; 7(293):293ra104. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. PMID: 26109104; PMCID: PMC4587492.
      View in: PubMed   Mentions: 182     Fields:    Translation:HumansCells
    59. FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. AJR Am J Roentgenol. 2015 Aug; 205(2):W150-61. Pasha MA, Marcus C, Fakhry C, Kang H, Kiess AP, Subramaniam RM. PMID: 26001119.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    60. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol. 2015 Jun; 26(6):1216-1223. Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA. PMID: 25712460; PMCID: PMC4516044.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCells
    61. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2015 Jan; 12(1):11-26. Kang H, Kiess A, Chung CH. PMID: 25403939.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCells
    62. FDG PET/CT in the management of nasopharyngeal carcinoma. AJR Am J Roentgenol. 2014 Aug; 203(2):W146-57. Mohandas A, Marcus C, Kang H, Truong MT, Subramaniam RM. PMID: 25055290.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    63. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2230-2236. Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. PMID: 25081901; PMCID: PMC4207729.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    64. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. J Nucl Med. 2014 Sep; 55(9):1411-6. Marcus C, Ciarallo A, Tahari AK, Mena E, Koch W, Wahl RL, Kiess AP, Kang H, Subramaniam RM. PMID: 24947059; PMCID: PMC4390037.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    65. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer. 2014 May 01; 120(9):1394-400. Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR, Brandes JC. PMID: 24664792; PMCID: PMC4102261.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    66. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila). 2014 Mar; 7(3):351-61. Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR, Vertino PM, Brandes JC. PMID: 24441677; PMCID: PMC3955098.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    67. Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis. Am J Hypertens. 2013 Feb; 26(2):287-97. Alviar CL, Devarapally S, Nadkarni GN, Romero J, Benjo AM, Javed F, Doherty B, Kang H, Bangalore S, Messerli FH. PMID: 23382415.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology. 2011 Jun; 152(6):2164-73. Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. PMID: 21447628; PMCID: PMC3100627.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    69. Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol. 2011 Mar; 12(1):96-106. Kang H, Kauh JS. PMID: 21274667.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    70. Green tea consumption and stomach cancer risk: a meta-analysis. Epidemiol Health. 2010 Apr 26; 32:e2010001. Kang H, Rha SY, Oh KW, Nam CM. PMID: 21191454; PMCID: PMC2984861.
      View in: PubMed   Mentions: 19     Fields:    
    71. [The determinants of adolescent smoking by gender and type of school in Korea]. J Prev Med Public Health. 2006 Sep; 39(5):379-88. Kim H, Kim EK, Choi ES, Kim YJ, Lee HJ, Kim JJ, Jang HS, Shim KS, Jeon SN, Kang YH, Kang H, Oh J, Cho KS, Kwon S. PMID: 17076178.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    72. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res. 2000 Jan; 6(1):193-202. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. PMID: 10656450.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    Hyunseok's Networks
    Concepts (293)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (34)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-4-g3cb31450 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.